Influence of teniposide on platelet functions in vitro

Kubisz, Peter; Seghier, F.; Dobrotorá, M.; Staško, Ján; Cronberg, S

doi:10.1016/0049-3848(95)91620-z

Cited by 6 publications

(2 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…administration and extension sets as well as solution containers continues to be a disadvantage of this diluted formulation (Vyas and Kadow 1995). What's more, VUMON can cause several severe side effects such as hypersensitivity, hypertension, hypoeosinophilia, and hematological toxicity (Carstensen, Nolte et al 1989;Kubisz, Seghier et al 1995;Weller, Muller et al 2003;Mane, Fernandez et al 2004). These are most probably caused by the surfactant Cremophor contained in the vehicle, rather than the drug itself (Gelderblom, Verweij et al 2001).…”

Section: Introductionmentioning

confidence: 94%

Cremophor-free intravenous self-microemulsions for teniposide: Safety, antitumor activity in vitro and in vivo

Cui

Wang

et al. 2015

International Journal of Pharmaceutics

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 94%

Cremophor-free intravenous self-microemulsions for teniposide: Safety, antitumor activity in vitro and in vivo

Cui

Wang

et al. 2015

International Journal of Pharmaceutics

View full text Add to dashboard Cite

“…Also, Cremophor may affect red blood cells because the surfactant can penetrate biological membranes to cause an increase in permeability and cell damage. A change in the shape of human white blood cells (WBCs) has also been reported in the studies on the Cremophor (12)(13)(14). Hence, monitoring the WBC and platelet count needs to be executed regularly during VUMON administration in clinic (15).…”

Section: Introductionmentioning

confidence: 96%

A Cremophor-Free Self-Microemulsified Delivery System for Intravenous Injection of Teniposide: Evaluation In Vitro and In Vivo

Cui

Dong

et al. 2012

AAPS PharmSciTech

View full text Add to dashboard Cite

In order to tackle the problems on low water solubility of teniposide, involvement of toxic surfactant in its injection, and the poor stability during infusion, a Cremophor-free teniposide self-microemulsified drug delivery system (TEN-SMEDDS) was prepared for the first time, characterized, and evaluated in comparison with teniposide injection (VUMON) in vitro and in vivo. The optimized formulation contained N, N-dimethylacetamide, medium-chain triglyceride, lecithin, and dehydrated alcohol besides teniposide. The TEN-SMEDDS could form fine droplets with mean diameter of 282 ± 21 nm and zeta potential of -7.5 ± 1.7 mV after dilution with 5% glucose, which were stable within 4 h. The release of teniposide from TEN-SMEDDS and VUMON was similar. However, the pharmacokinetic behavior of TEN-SMEDDS in rats was different from that of VUMON, evidenced by the lower area under the concentration-time curve and larger volume of distribution in emulsion group. Finally, TEN-SMEDDS was found to distribute more teniposide in most tissues, especially in reticuloendothelial system, after intravenous administration to rats. Importantly, brain drug level in TEN-SMEDDS group was higher than or similar to that in control group, although the emulsion system had a lower plasma drug concentration. In conclusion, the novel SMEDDS prepared here, without toxic surfactant and as an oil solution before use, may be potential for clinical use due to its low toxicity and high store stability. It may be favorable for the treatment of some tumors like cerebroma, since it may achieve the relatively higher drug level in brain but lower blood concentration.

show abstract

Preparation and in vitro – in vivo evaluation of teniposide nanosuspensions

Yang

Zhang

et al. 2015

International Journal of Pharmaceutics

View full text Add to dashboard Cite

Influence of teniposide on platelet functions in vitro

Cited by 6 publications

References 2 publications

Cremophor-free intravenous self-microemulsions for teniposide: Safety, antitumor activity in vitro and in vivo

Cremophor-free intravenous self-microemulsions for teniposide: Safety, antitumor activity in vitro and in vivo

A Cremophor-Free Self-Microemulsified Delivery System for Intravenous Injection of Teniposide: Evaluation In Vitro and In Vivo

Preparation and in vitro – in vivo evaluation of teniposide nanosuspensions

Contact Info

Product

Resources

About